|
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
Oct 2024 |
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
|
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
Sep 2024 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
Sep 2024 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
Sep 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
